Manufacturers report positive results for vadadustat for anaemia due to chronic kidney disease in adults on dialysis

In the INNO2VATE studies, vadadustat, (a hypoxia-inducible factor-prolyl hydroxylase inhibitor) was found to be non-inferior to darbepoetin for change in baseline haemoglobin (primary endpoint), and time to first occurrence of major adverse cardiovascular events (safety endpoint)

Biospace Inc.